Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 30

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 30
---
 opportunities that may develop in the equity markets.

We are seeking stockholder approval for the potential issuance of shares of our common stock, or securities convertible into our common stock, in one or more capital-raising transactions, or offerings, subject to the following limitations:

| ● | The aggregate number of                                                                                                                  
 shares issued in the offerings will not exceed 10 million shares of our common stock, subject to adjustment for any reverse stock        
 split effected prior to the offerings (including pursuant to preferred stock, options, warrants, convertible debt or other securities    
 exercisable for or convertible into Common Stock);                                                                                       |
| ● | The total aggregate consideration                                                                                                        
 will not exceed $10,000,000 in cash;                                                                                                     |
| ● | The maximum discount in which securities will be offered (which may consist                                                              
 of a share of common stock and a warrant for the issuance of up to an additional share of common stock) will be equivalent to a discount 
 of up to 35% below the market price of our common stock at the time of issuance in recognition of the limited public float of our traded 
 common stock and historical volatility making the pricing discount of our stock required by investors at any particular time difficult,  
 at this time, to predict;;                                                                                                               |
| ● | Such offerings will occur,                                                                                                               
 if at all, on or before December 31, 2026; and                                                                                           |
| ● | Such other terms as our                                                                                                                  
 Board of Directors shall deem to be in the best interests of the Company and its stockholders, not inconsistent with the foregoing.      |

The issuance of shares of our common stock, or other securities convertible into shares of our common stock, in accordance with any offerings would dilute, and thereby reduce, each existing stockholder’s proportionate ownership in our common stock.

The issuance of shares of common stock in one or more non-public offerings could have an anti-takeover effect. Such issuance could dilute the voting power of a person seeking control of the Company, thereby deterring or rendering more difficult a merger, tender offer, proxy contest or an extraordinary corporate transaction opposed by the Company.

Our Board of Directors has not yet determined the terms and conditions of any offerings. As a result, the level of potential dilution cannot be determined at this time, but as discussed above, we may not issue more than 10 million shares of common stock in the aggregate pursuant to the authority requested from stockholders under this proposal (subject to adjustment for any reverse stock split). It is possible